home / stock / rlyb / rlyb quote
Last: | $1.63 |
---|---|
Change Percent: | -1.81% |
Open: | $1.62 |
Close: | $1.66 |
High: | $1.63 |
Low: | $1.62 |
Volume: | 2,161 |
Last Trade Date Time: | 06/14/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.63 | $1.62 | $1.66 | $1.63 | $1.62 | 2,161 | 06-14-2024 |
$1.66 | $1.64 | $1.66 | $1.68 | $1.6 | 93,826 | 06-13-2024 |
$1.65 | $1.6 | $1.65 | $1.7291 | $1.6 | 180,950 | 06-12-2024 |
$1.64 | $1.49 | $1.64 | $1.64 | $1.49 | 154,174 | 06-11-2024 |
$1.525 | $1.45 | $1.525 | $1.55 | $1.44 | 148,681 | 06-10-2024 |
$1.48 | $1.52 | $1.48 | $1.54 | $1.46 | 115,165 | 06-07-2024 |
$1.49 | $1.57 | $1.49 | $1.6 | $1.49 | 149,948 | 06-06-2024 |
$1.61 | $1.55 | $1.61 | $1.62 | $1.51 | 137,893 | 06-05-2024 |
$1.54 | $1.54 | $1.54 | $1.6 | $1.53 | 129,854 | 06-04-2024 |
$1.55 | $1.66 | $1.55 | $1.6816 | $1.53 | 123,981 | 06-03-2024 |
$1.67 | $1.6 | $1.67 | $1.69 | $1.5957 | 163,502 | 05-31-2024 |
$1.59 | $1.48 | $1.59 | $1.66 | $1.48 | 323,353 | 05-30-2024 |
$1.47 | $1.58 | $1.47 | $1.58 | $1.44 | 275,224 | 05-29-2024 |
$1.58 | $1.57 | $1.58 | $1.63 | $1.55 | 211,234 | 05-28-2024 |
$1.56 | $1.61 | $1.56 | $1.65 | $1.56 | 180,887 | 05-27-2024 |
$1.56 | $1.61 | $1.56 | $1.65 | $1.56 | 180,887 | 05-24-2024 |
$1.61 | $1.71 | $1.61 | $1.71 | $1.6 | 148,115 | 05-23-2024 |
$1.71 | $1.68 | $1.71 | $1.73 | $1.66 | 173,819 | 05-22-2024 |
$1.61 | $1.63 | $1.61 | $1.7 | $1.57 | 274,617 | 05-21-2024 |
$1.59 | $1.77 | $1.59 | $1.84 | $1.59 | 490,305 | 05-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Rallybio Corporation Company Name:
RLYB Stock Symbol:
NASDAQ Market:
- On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk of FNAIT in 2H 2024 - - $94.2 Million in Cash, Cash Equivalents, and Marketable Securities as of March 31, 2024; Provides Runway into Mid-2026 - Rallybio Corporation (Nasdaq: RLYB), a...
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will partici...